References
1. Murphy BA, Ridner S, Wells N, et al. Quality of life research in head and neck cancer: a review of the current state of the science. Crit Rev Oncol Hematol 2007;62:251-267.
2. de Haes J, Curran D, Young T, et al. Quality of life evaluation in oncological clinical trials--the EORTC model. The EORTC Quality of Life Study Group. Eur J Cancer 2000;36:821-825.
3. Movsas B. Quality of life in oncology trials: a clinical guide. Semin Radiat Oncol 2003;13:235-247.
4. Hassan SJ, Weymuller EA Jr. Assessment of quality of life in head and neck cancer patients. Head Neck 1993;15:485-496.
5. List MA, Ritter-Sterr C, Lansky SB. A performance status scale for head and neck cancer patients. Cancer 1990;66:564-569.
6. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-98.
7. Bourhis J, Amand C, Pignon JP. Update of MACH-NC (meta-analysis of chemotherapy in head and neck cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol 2004;22:5505.
8. Rosenthal DI, Ang KK. Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma. Semin Radiat Oncol 2004;14:153-166.
9. Corvo R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 2007;85:156-170.
10. Aggarwal SK. Calcium modulation of toxicities due to cisplatin. Met Based Drugs 1998;5:77-81.
11. Epstein JB, Thariat J, Bensadoun RJ, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin 2012;62:400-422.
12. Karnofsky DA, Burchenal JH. The evaluation of therapeutics in cancer. In Macleod CM ed. Evaluation of Chemotherapeutic Agents. New York: Columbia University Press; 1949:191-205.
13. Whitcomb DC, Yadav D, Adam S, et al. Multicenter approach to recurrent acute and chronic pancreatitis in the United States: the North American Pancreatitis Study 2 (NAPS2). Pancreatology 2008;8:520-531.
14. Jindal SK, Malik SK, Dhand R, et al. Bronchogenic carcinoma in northern India. Thorax 1982;37:343-347.
15. Rogers SN, Lowe D, Fisher SE, et al. Health-related quality of life and clinical function after primary surgery for oral cancer. Br J Oral Maxillofac Surg 2002;40:11-18.
16. Vartanian JG, Carvalho AL, Yueh B, et al. Brazilian-Portuguese validation of the University of Washington Quality of Life Questionnaire for patients with head and neck cancer. Head Neck 2006;28:1115-1121.
17. Karvonen-Gutierrez CA1, Ronis DL, Fowler KE, et al. Quality of life scores predict survival among patients with head and neck cancer. J Clin Oncol 2008;26:2754-2760.
18. Terrell JE, Ronis DL, Fowler KE, et al. Clinical predictors of quality of life in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2004;130:401-408.
19. Terrell JE, Fisher SG, Wolf GT. Long-term quality of life after treatment of laryngeal cancer. The Veterans Affairs Laryngeal Cancer Study Group. Arch Otolaryngol Head Neck Surg 1998;124:964-971.
20. Hillman RE, Walsh MJ, Wolf GT, et al. Functional outcomes following treatment for advanced laryngeal cancer. Part I: voice preservation in advanced laryngeal cancer. Part II: laryngectomy rehabilitation: the state of the art in the VA System. Research Speech-Language Pathologists. Department of Veterans Affairs Laryngeal Cancer Study Group. Ann Otol Rhinol Laryngol Suppl 1998;172:1-27.
21. Shun SC, Chen CH, Sheu JC, et al. Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study. Oncologist 2012;17:732-739.
22. Gridelli C, Perrone F, Nelli F, et al. Quality of life in lung cancer patients. Ann Oncol 2001;12(Suppl 3):S21-S25.
23. Roland NJ, Bradley PJ. The role of surgery in the palliation of head and neck cancer. Curr Opin Otolaryngol Head Neck Surg 2014;22:101-108.
24. List MA, Bilir SP. Functional outcomes in head and neck cancer. Semin Radiat Oncol 2004;14:178-189.
25. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:1161-1171.
26. List MA, Ritter-Sterr CA, Baker TM, et al. Longitudinal assessment of quality of life in laryngeal cancer patients. Head Neck 1996;18:1-10.
27. Magne´ N, Marcy PY, Chamorey E, et al. Concomitant twice-a-day radiotherapy and chemotherapy in unresectable head and neck cancer patients: a long-term quality of life analysis. Head Neck 2001;23:678-682.
28. Vokes EE, Kies MS, Haraf DJ, et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000;18:1652-1661.
29. List MA, Mumby P, Haraf D, et al. Performance and quality of life outcome in patients completing concomitant chemoradiotherapy protocols for head and neck cancer. Qual Life Res 1997;6:274-284.
30. Visacri MB, Ferrari GB, Pimentel R, et al. Evaluation of quality of life of patients before treatment of squamous cell carcinoma of the head and neck by means of chemoradiotherapy. Contemp Oncol (Pozn) 2015;19:148-153.
31. Konings AW, Coppes RP, Vissink A. On the mechanism of salivary gland radiosensitivity. Int J Radiat Oncol Biol Phys 2005;62:1187-1194.